TEAL Study

Investigator: Jenny Chang, MD

Study Coordinator: Toniva Boone

Status: Enrolling

ClinicalTrials.gov Number: NCT02073487

Phone: 713.441.0686

IRB Number: Pro00010074


The purpose of this study is to evaluate the Pathological Complete Response (pCR) of the breast when trastuzumab emtansine (TDM-1) plus Lapatinib plus Abraxane is combined in newly diagnosed HER2 positive breast cancer.
More to Explore